Recombinant Human Olfactory receptor 6P1 (OR6P1)

What is OR6P1 and how is it classified?

OR6P1 (Olfactory receptor 6P1, also known as Olfactory receptor OR1-12) belongs to the Class O2 (tetrapod specific odorant) Olfactory receptor family 6. It functions as an odorant receptor that interacts with odorant molecules in the nose to initiate neuronal responses that trigger smell perception . OR6P1 is currently categorized among targets about which relatively little is known (Tdark category), with limited published literature (Pubmed score: 0.28) and no established Gene RIFs .

What is the molecular structure of OR6P1?

OR6P1 is a G protein-coupled receptor (GPCR) with the characteristic seven-transmembrane domain structure. The protein sequence begins with an N-terminal region, followed by seven transmembrane domains (TM1-TM7) connected by alternating intracellular and extracellular loops . The complete amino acid sequence is available in protein databases, with specific structural motifs that are conserved among class O2 olfactory receptors. As with many ORs, detailed three-dimensional structural information remains limited due to challenges in crystallization of membrane proteins.

What is currently known about physiological ligands for OR6P1?

Currently, no physiological ligands have been definitively identified for OR6P1 . This classifies it as an "orphan receptor" - a receptor whose endogenous ligand(s) remain unknown. The identification of natural and synthetic ligands represents a significant knowledge gap in OR6P1 research. Similar olfactory receptors like OR6M1 have had ligands identified through techniques such as surface plasmon resonance (SPR) screening against chemical libraries .

What are the recommended methods for recombinant expression of OR6P1?

For successful recombinant expression of OR6P1, researchers should consider the following methodology:

• Vector Construction: Design an expression vector containing the OR6P1 gene with appropriate tags (e.g., GST) to aid in purification and detection. The GST tag can be fused to the N-terminus of OR6P1 .

• Chaperone Co-expression: Include receptor-transporting proteins (RTPs), particularly RTP1, in the expression system to facilitate proper folding and membrane trafficking. This is critical as ORs generally show poor surface expression in heterologous cells without chaperones .

• Expression System Selection: HEK293T/17 cells have been successfully used for expressing similar olfactory receptors. After transfection, select stable expressors using appropriate antibiotics (e.g., puromycin at 5 μg/mL) .

• Confirmation of Expression: Verify successful expression through immunofluorescence using antibodies against the fusion tag and western blotting techniques .

How can researchers overcome challenges in membrane localization of OR6P1?

Unlike many other GPCRs, olfactory receptors require specific chaperone proteins to facilitate successful surface expression. To overcome the challenge of poor membrane localization:

• Co-express OR6P1 with receptor-transporting proteins such as RTP1, RTP2, or REEP1. Among these, RTP1 or its shorter form RTP1s has shown particular effectiveness in facilitating OR membrane expression .

• Consider using a bicistronic vector system that allows simultaneous expression of both OR6P1 and the chaperone protein from a single transcript, such as the pIRES system .

• Evaluate membrane localization through immunofluorescence by fixing cells with 4% paraformaldehyde, then using primary antibodies against the tag (e.g., GST) followed by fluorescently-labeled secondary antibodies .

• Compare expression efficiency in different cell lines, as some may provide a more favorable environment for proper OR6P1 folding and trafficking.

What methods can be used to identify potential ligands for orphan OR6P1?

For identifying potential ligands for orphan receptors like OR6P1, a multi-tiered approach similar to that used for OR6M1 is recommended:

• Primary Screening: Employ surface plasmon resonance (SPR) biosensor systems with immobilized OR6P1-expressing whole cells. This allows for direct observation of binding between the receptor and potential ligands .

• Secondary Screening: Prepare OR6P1-expressing membrane fragments (average size ~120-150 nm) and immobilize them on SPR chips for higher sensitivity screening. Membrane fragments provide several advantages over whole cells:

  • Reduced size (approximately 70-times smaller than whole cells)

  • Decreased nonspecific binding

  • Improved assay sensitivity

  • Maintained receptor structural stability

• Confirmation Assays: Following identification of potential ligands through SPR, verify functional activity using calcium imaging assays in OR6P1-expressing cells that co-express appropriate signaling components .

How can calcium imaging be optimized for OR6P1 functional studies?

To optimize calcium imaging for OR6P1 functional studies:

• Cell Preparation: Use Hana3A cells (which stably express RTP1, RTP2, and REEP1) or similarly prepared cells transiently transfected with OR6P1 expression constructs .

• Calcium Indicator Loading: Incubate cells with calcium-sensitive dyes such as Fluo-4 AM in a buffer containing physiological concentrations of calcium.

• Experimental Setup: Mount cells in a perfusion chamber on a fluorescence microscope equipped with appropriate excitation/emission filters.

• Response Measurement: Record baseline fluorescence before applying potential ligands, then monitor changes in fluorescence intensity that indicate calcium influx.

• Data Analysis: Calculate the relative fluorescence change (ΔF/F0) for quantification of responses to different compounds at various concentrations.

• Agonist/Antagonist Classification: Classify compounds that increase calcium influx as agonists, while those that block agonist-induced calcium influx can be classified as antagonists .

What techniques are currently applicable for studying OR6P1 structure?

Given the challenges in crystallizing membrane proteins, especially GPCRs, the following approaches are recommended for structural studies of OR6P1:

• Homology Modeling: Create computational models based on crystal structures of other GPCRs, taking into account the known seven-transmembrane domain structure of OR6P1 .

• Cryo-Electron Microscopy (Cryo-EM): This technique has revolutionized membrane protein structural biology and may be applicable to OR6P1, particularly if it can be stabilized in detergent micelles or nanodiscs.

• Site-Directed Mutagenesis: Systematically alter specific residues predicted to be involved in ligand binding or receptor activation to indirectly probe the structure-function relationship.

• Molecular Dynamics Simulations: Use computational approaches to simulate OR6P1 behavior in a membrane environment, providing insights into dynamic structural changes.

How should researchers design an SPR-based screening approach for OR6P1 ligand discovery?

To design an effective SPR-based screening approach for OR6P1 ligand discovery:

• Biosensor Preparation:

  • Generate stable OR6P1-expressing cell lines using the methodology described in Section 2.1

  • For cell-based biosensors, immobilize OR6P1-expressing cells by covalent bonding between cell surface aldehyde groups and carbohydrazide on the SPR chip surface

  • For membrane fragment biosensors, isolate membrane fragments from OR6P1-expressing cells and immobilize them on the SPR chip

• Screening Protocol:

  • Select a diverse chemical library for screening

  • Run compounds at appropriate concentrations (e.g., 15-25 μM)

  • Monitor SPR response (ΔRU) over time (typically 900-1100 seconds)

  • Compare binding to OR6P1-expressing cells/fragments versus control cells/fragments

  • Perform concentration-dependent binding studies for hit confirmation

• Data Analysis:

  • Identify compounds that show specific binding to OR6P1 over controls

  • Calculate binding parameters such as association and dissociation rates

  • Prioritize hits showing concentration-dependent responses

What controls are essential for validating OR6P1 ligand binding assays?

For rigorous validation of OR6P1 ligand binding assays, the following controls are essential:

• Negative Controls:

  • Non-transfected parental cells (e.g., HEK293T/17) to control for non-specific binding

  • Membrane fragments from non-transfected cells

  • Known non-ligands for olfactory receptors

• Positive Controls:

  • If available, structurally related olfactory receptors with known ligands

  • Concentration gradients of potential ligands to demonstrate dose-dependency

  • Competitive binding assays once initial ligands are identified

• Validation Steps:

  • Verify protein expression levels between test and control samples

  • Ensure consistent immobilization levels on SPR chips

  • Conduct multiple independent experiments to ensure reproducibility

How might OR6P1 be relevant to cancer research based on studies of related olfactory receptors?

Based on findings with the related receptor OR6M1, OR6P1 may have potential relevance to cancer research:

• Expression Analysis: Researchers should first determine whether OR6P1 is expressed in various cancer cell lines at both the mRNA level (using PCR) and protein level (using western blotting), similar to how OR6M1 was identified in MCF-7 breast cancer cells .

• Functional Role Investigation: If OR6P1 is expressed in cancer cells, researchers should investigate its potential role in:

  • Cell proliferation and viability

  • Cell migration and invasion

  • Apoptotic pathways

  • Cell cycle regulation

• Therapeutic Potential: Should OR6P1 ligands be identified, they could be evaluated for anticancer activity. For instance, the OR6M1 agonist anthraquinone (AQ) was found to induce death of MCF-7 cells, suggesting that olfactory receptors may represent novel anticancer targets .

What methods can be used to investigate OR6P1's potential role in cancer cells?

To investigate OR6P1's potential role in cancer:

• Expression Analysis:

  • Perform RT-PCR and qPCR to quantify OR6P1 mRNA expression

  • Use western blotting with specific antibodies to detect protein expression

  • Apply immunohistochemistry to localize OR6P1 in tissue samples

• Functional Assays:

  • Cell Viability: Use MTT or MTS assays to measure cell proliferation after OR6P1 activation or inhibition

  • Apoptosis Detection: Employ flow cytometry with Annexin V/PI staining to quantify apoptotic cells

  • Migration Assays: Utilize wound healing or transwell assays to assess effects on cell migration

  • Signaling Pathway Analysis: Investigate downstream signaling using phosphorylation-specific antibodies for key pathway proteins

• Genetic Manipulation:

  • Perform siRNA or shRNA knockdown of OR6P1 to observe phenotypic changes

  • Create OR6P1 overexpression models to study gain-of-function effects

How can researchers determine the signaling pathways activated by OR6P1?

To elucidate signaling pathways downstream of OR6P1 activation:

• G Protein Coupling Analysis:

  • Perform [35S]GTPγS binding assays to determine which G protein subtypes couple with OR6P1

  • Use selective G protein inhibitors to examine their effects on OR6P1-mediated responses

  • Employ BRET (Bioluminescence Resonance Energy Transfer) assays to directly measure OR6P1-G protein interactions

• Second Messenger Measurements:

  • Monitor cAMP levels using ELISA or FRET-based sensors to assess Gαs/Gαi coupling

  • Measure IP3 production and calcium mobilization to evaluate Gαq coupling

  • Examine β-arrestin recruitment using protein complementation assays

• Kinase Activation Profiling:

  • Assess phosphorylation of ERK1/2, PKA, PKC, and other kinases via western blotting

  • Employ kinase inhibitors to determine the importance of specific pathways

  • Use phospho-specific antibody arrays to broadly profile kinase activation

What are the best approaches for developing selective OR6P1 modulators?

For development of selective OR6P1 modulators:

• Structure-Based Design:

  • Generate homology models of OR6P1 based on available GPCR crystal structures

  • Perform in silico docking studies to identify potential binding pockets

  • Utilize molecular dynamics simulations to understand ligand-receptor interactions

• High-Throughput Screening Optimization:

  • Develop cell-based functional assays suitable for high-throughput format

  • Screen diverse chemical libraries against OR6P1-expressing cells

  • Implement counter-screening against related ORs to assess selectivity

• Medicinal Chemistry Approaches:

  • Once hit compounds are identified, establish structure-activity relationships

  • Synthesize focused libraries around promising scaffolds

  • Optimize for potency, selectivity, and drug-like properties

• Validation Studies:

  • Confirm binding using biophysical methods like SPR

  • Verify functional activity through calcium imaging or other signaling assays

  • Assess selectivity against a panel of related olfactory receptors

What are the key challenges in working with recombinant OR6P1?

Researchers working with recombinant OR6P1 should be aware of these key challenges:

How should researchers approach contradictory results in OR6P1 studies?

When encountering contradictory results in OR6P1 research:

• Methodological Evaluation:

  • Compare experimental conditions across studies, including expression systems, tags, and assay formats

  • Assess the impact of different chaperone proteins on OR6P1 function

  • Consider cell type-specific factors that might influence receptor behavior

• Statistical Rigor:

  • Ensure adequate replication and appropriate statistical analyses

  • Evaluate effect sizes rather than focusing solely on statistical significance

  • Consider power calculations to determine if sample sizes are sufficient

• Orthogonal Validation:

  • Confirm key findings using multiple, independent methodologies

  • Employ both binding and functional assays to corroborate results

  • Verify antibody specificity through appropriate controls

• Contextual Factors:

  • Assess the impact of receptor density on signaling outcomes

  • Consider the influence of cellular microenvironment on receptor function

  • Evaluate potential differences between recombinant systems and native contexts